Vessi Medical

Company Overview

Snapshot

Founded in June 2015 by Eyal Kochavi, Vessi Medical operates with 1–10 employees. The company has raised $18.2 million across two funding rounds from six investors. In February 2024, Vessi Medical closed a Series A round, signaling strong investor confidence in its innovative cryotherapy solution for bladder cancer.

Business overview

Vessi Medical is developing a novel approach for treating superficial urological tissue, specifically bladder cancer, using surface cryotherapy. This technology utilizes extreme cold to freeze and destroy abnormal tissue. The Vessi Medical system comprises a stand-alone console and a disposable catheter, designed to be inserted into the bladder via existing intravesical techniques. This minimally invasive solution offers a therapeutic alternative to traditional surgery, aiming to reduce costs and complications associated with current treatments in the Health Tech & Life Sciences sector, particularly within Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In February 2024, Vessi Medical successfully closed a $16.5 million Series A funding round. This significant capital injection validates the company's progress, particularly following promising results from its first-in-human clinical study in 2023, and provides crucial resources for advancing its innovative cryotherapy bladder cancer treatment through further development and market entry.

Company Intelligence Q&A

What was the most recent funding event for Vessi Medical?

In February 2024, Vessi Medical closed a Series A funding round, raising $16.5 million. ALIVE Israel Healthtech Fund led this round, with participation from Agriline and The Trendlines Group.

Who founded Vessi Medical?

Vessi Medical was founded by Eyal Kochavi in June 2015.

What is Vessi Medical's core technology?

Vessi Medical develops a surface cryotherapy system that uses extreme cold to freeze and destroy abnormal superficial urological tissue, offering a minimally invasive treatment for conditions like bladder cancer.

Has Vessi Medical conducted clinical trials for its technology?

Yes, Vessi Medical finalized its first-in-human clinical study in 2023, reporting very promising results for its cryotherapy treatment for urological tissue.

What was the company's earlier funding activity?

In March 2020, Vessi Medical secured a Seed funding round. The Trendlines Group led this round, which also included participation from Agriline and Israel Innovation Authority